Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8666049 | 0.96 | L3MBTL1 (0.34) | L3MBTL1HTTMAPK1LMNA | |
| SCHEMBL8504369 | 0.93 | HTT (0.31) | L3MBTL1HTT | |
| SCHEMBL8479389 | 0.89 | DPP4 (0.38) | ALDH1A1 | |
| SCHEMBL8665216 | 0.81 | CCR3 (0.39) | — | |
| SCHEMBL8484431 | 0.79 | L3MBTL1 (0.35) | L3MBTL1HTTMAPK1LMNATSHR | |
| SCHEMBL8500946 | 0.79 | CCR3 (0.36) | — | |
| SCHEMBL8666043 | 0.77 | HTT (0.33) | L3MBTL1HTTMAPK1LMNA | |
| SCHEMBL8504363 | 0.75 | KCNA5 (0.30) | — | |
| SCHEMBL8679135 | 0.74 | L3MBTL1 (0.36) | L3MBTL1HTTMAPK1LMNATSHR | |
| SCHEMBL8648481 | 0.73 | CCR3 (0.39) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-H1729-H | Method for preparing compounds employing solid phase synthesis and novel linker-resin | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |